W. Lane

发表

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)

G. Sesti, E. Franek, H. Jang, 2020, Diabetes Care.

The effect of addition of liraglutide to high‐dose intensive insulin therapy: a randomized prospective trial

W. Lane, S. Weinrib, J. Rappaport, 2014, Diabetes, obesity & metabolism.

Successful management of differentiated thyroid cancer in a community-based endocrine practice.

W. Lane, S. Weinrib, J. Rappaport, 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables

J. Gundgaard, J. Weatherall, R. Pollock, 2018, Journal of medical economics.

A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance.

W. Lane, S. Weinrib, J. Rappaport, 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study

P. Lapuerta, J. Rosenstock, J. Kushner, 2018, Diabetes Care.

Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance.

W. Lane, 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes.

W. Lane, R. Lane, S. Weinrib, 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Comment on Feig et al. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care 2018;41:2471–2479

W. Lane, Julia M Sacha, 2019, Diabetes Care.

AACE/ACE Consensus Statement

P. Raskin, W. Tamborlane, G. Grunberger, 2014 .

Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force.

Bruce W Bode, Richard Hellman, Timothy S Bailey, 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial

G. Sesti, E. Franek, E. Jódar, 2022, Diabetes Therapy.

Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial.

Claresa Levetan, Bruce Bode, J. Mastrototaro, 2004, Mayo Clinic proceedings.

The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.

W. Lane, S. Weinrib, J. Rappaport, 2011, Diabetes technology & therapeutics.

High-dose insulin therapy: is it time for U-500 insulin?

I. Hirsch, J. Scism-Bacon, J. Skyler, 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Basal Insulin degludec and GLycemic control ComparEd to Aspart via insulin Pump in type 1 diabetes (BIGLEAP): a single-center, open-label, randomized, crossover trial.

W. Lane, S. Weinrib, Ryan T. Jarrett, 2021, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM findings from the VIVID study.

D. Rodbard, T. Ly, D. Sindelar, 2020, Diabetes technology & therapeutics.

Hypoglycemia with Mealtime Fast-Acting Insulin Aspart vs. Insulin Aspart Across Two Large Type 1 Diabetes Trials

A. Gorst-rasmussen, T. Gondolf, C. Block, 2018, Diabetes.

Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

I. Hirsch, S. Garg, B. Bode, 2005, Diabetes care.